CA2593266A1 - Aryl piperazine derivatives for the treatment of neuropsychiatric disorders - Google Patents

Aryl piperazine derivatives for the treatment of neuropsychiatric disorders Download PDF

Info

Publication number
CA2593266A1
CA2593266A1 CA002593266A CA2593266A CA2593266A1 CA 2593266 A1 CA2593266 A1 CA 2593266A1 CA 002593266 A CA002593266 A CA 002593266A CA 2593266 A CA2593266 A CA 2593266A CA 2593266 A1 CA2593266 A1 CA 2593266A1
Authority
CA
Canada
Prior art keywords
alkyl
butyl
piperazin
cycloalkyl
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002593266A
Other languages
English (en)
French (fr)
Inventor
Stefania Butini
Caterina Fattorusso
Francesco Trotta
Silvia Franceschini
Meri De Angelis
Karin Sandager Nielsen
Giuseppe Campiani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universita degli Studi di Siena
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2593266A1 publication Critical patent/CA2593266A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
CA002593266A 2005-01-03 2006-01-02 Aryl piperazine derivatives for the treatment of neuropsychiatric disorders Abandoned CA2593266A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200500004 2005-01-03
DKPA200500004 2005-01-03
US64100605P 2005-01-04 2005-01-04
US60/641,006 2005-01-04
PCT/EP2006/050001 WO2006072608A2 (en) 2005-01-03 2006-01-02 Aryl piperazine derivatives for the treatment of neuropsychiatric disorders

Publications (1)

Publication Number Publication Date
CA2593266A1 true CA2593266A1 (en) 2006-07-13

Family

ID=36600734

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002593266A Abandoned CA2593266A1 (en) 2005-01-03 2006-01-02 Aryl piperazine derivatives for the treatment of neuropsychiatric disorders

Country Status (7)

Country Link
US (1) US20090238761A1 (enExample)
EP (1) EP1836192A2 (enExample)
JP (1) JP2008526715A (enExample)
AU (1) AU2006204522A1 (enExample)
CA (1) CA2593266A1 (enExample)
NZ (1) NZ555491A (enExample)
WO (1) WO2006072608A2 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2903986A1 (fr) * 2006-07-21 2008-01-25 Pierre Fabre Medicament Sa Nouveaux derives chromenes ou thiochromenes carboxamides, leur procede de preparation et leurs applications en therapeutique
GB0615809D0 (en) * 2006-08-09 2006-09-20 Istituto Di Ricerche D Biolog Therapeutic compounds
WO2008043839A1 (en) * 2006-10-13 2008-04-17 Università Degli Studi Di Siena Aryl piperazine derivatives useful for the treatment of neuropsychiatry disorders
WO2008082887A2 (en) 2006-12-28 2008-07-10 Abbott Laboratories Inhibitors of poly(adp-ribose)polymerase
CA2690789C (en) * 2007-06-15 2014-08-05 Amy Hauck Newman 4-phenylpiperazine derivatives with functionalized linkers as dopamine d3 receptor selective ligands and methods of use
CN101784541A (zh) * 2007-06-25 2010-07-21 纽罗根公司 哌嗪基氧代烷基四氢-β-咔啉及相关类似物
WO2009095438A1 (en) * 2008-02-01 2009-08-06 Neurosearch A/S Novel aryl piperazine derivatives useful as modulators of dopamine and serotonin receptors
WO2010040808A1 (en) * 2008-10-10 2010-04-15 Neurosearch A/S Novel quinolinylamide derivatives useful as modulators of dopamine and serotonin receptors
RS55532B1 (sr) 2012-03-16 2017-05-31 Vitae Pharmaceuticals Inc Modulatori jetrenog x receptora
PT2825541T (pt) 2012-03-16 2016-09-28 Vitae Pharmaceuticals Inc Moduladores de recetor de fígado x
US9951088B2 (en) * 2012-05-09 2018-04-24 Sunovion Pharmaceuticals Inc. D2 receptor modulators and methods of use thereof in the treatment of diseases and disorders
JP6448541B2 (ja) * 2012-10-11 2019-01-09 サザン リサーチ インスティテュート アミノアルキルピペラジンの尿素及びアミド誘導体並びにその使用
PT2989105T (pt) * 2013-04-23 2020-04-22 Esteve Pharmaceuticals Sa Compostos de pirazino[1,2-a]indole, sua preparação e utilização em medicamentos
WO2015014256A1 (en) 2013-07-29 2015-02-05 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use thereof
CN104725359B (zh) 2013-12-20 2017-05-03 广东东阳光药业有限公司 取代的哌嗪化合物及其使用方法和用途
MA41168A (fr) * 2014-12-17 2017-10-24 Acraf Nouveaux composés antibactériens
WO2016115144A1 (en) * 2015-01-12 2016-07-21 Reviva Pharmaceuticals Inc. Methods for treating alzheimer's disease
JP2018502158A (ja) * 2015-01-12 2018-01-25 レビバ ファーマシューティカルズ，インコーポレイティド パーキンソン病と関連する精神病の治療方法
CN107206007B (zh) 2015-01-12 2021-08-10 雷维瓦药品公司 用于治疗肺高血压的方法
US10316025B2 (en) 2015-06-03 2019-06-11 Sunshine Lake Pharma Co., Ltd. Substituted piperazine compounds and methods of use and use thereof
ES2924371T3 (es) 2015-06-17 2022-10-06 Pfizer Compuestos tricíclicos y su uso como inhibidores de la fosfodiesterasa
EP3848351B1 (en) 2016-03-14 2025-01-15 The United States of America, as represented by The Secretary, Department of Health and Human Services Dopamine d3 receptor selective antagonists/partial agonists; method of making; and use thereof
US11299476B2 (en) 2016-03-14 2022-04-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dopamine D3 receptor selective antagonists/partial agonists; method of making; and use thereof
US12319659B2 (en) 2017-02-24 2025-06-03 Shenzhen Linglan Bio-Pharmaceutical Technology Co., Ltd Selective ligand for dopamine D3 receptor, preparation method therefor, and pharmaceutical application thereof
CN110382478A (zh) * 2017-03-13 2019-10-25 大日本住友制药株式会社 2,6-二取代的吡啶衍生物
GB201704325D0 (en) * 2017-03-17 2017-05-03 Argonaut Therapeutics Ltd Compounds
AU2019340675B2 (en) 2018-09-11 2024-06-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dopamine D3 receptor selective antagonists/partial agonists and uses thereof
MX2022015829A (es) 2020-06-11 2023-04-05 Chdi Foundation Inc Compuestos heterocíclicos y agentes formadores de imágenes para formar la imagen de la proteína huntingtina.

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2777849A (en) * 1954-07-23 1957-01-15 American Cyanamid Co 1, 1'-alkylenedipiperazines and methods of preparing same
US2837522A (en) * 1955-10-20 1958-06-03 American Cyanamid Co Substituted alkylenedipiperazines
US3646047A (en) * 1970-02-02 1972-02-29 American Cyanamid Co Certain benzo(b)thiophene-2-carboxamide derivatives
US3734915A (en) * 1970-02-02 1973-05-22 American Cyanamid Co N-(-(4-phenyl-1-piperazinyl)alkyl)benzo(b)thiophene or benzofuran-2-carboxamides
FR2187311B1 (enExample) * 1972-06-02 1975-06-20 Bouchara Emile
US4803203A (en) * 1986-11-05 1989-02-07 Warner-Lambert Company Phenyl and heterocyclic piperazinyl alkoxy-benzheterocyclic compounds as antipsychotic agents
US4954502A (en) * 1988-06-10 1990-09-04 Bristol-Myers Squibb Company 1-indolyalkyl-4-(substituted-pyridinyl)piperazines
DE3923675A1 (de) * 1989-07-18 1991-01-24 Basf Ag Amonoalkylsubstituierte 2-aminothiazole und diese enthaltende therapeutische mittel
FR2655988B1 (fr) * 1989-12-20 1994-05-20 Adir Cie Nouveaux derives de la napht-1-yl piperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
ES2027898A6 (es) * 1991-01-24 1992-06-16 Espanola Prod Quimicos Procedimiento de preparacion de nuevos derivados de la 2-metoxifenilpiperacina.
GB9306578D0 (en) * 1993-03-30 1993-05-26 Merck Sharp & Dohme Therapeutic agents
DE4425146A1 (de) * 1994-07-15 1996-01-18 Basf Ag Verwendung heterocyclischer Verbindungen
US6100255A (en) * 1998-10-28 2000-08-08 Neurogen Corporation 3-aminoalkylamino-2H-1,4-benzoxazines and 3-aminoalkylamino-2H-1,4-benzothiazines: dopamine receptor subtype specific ligands
JP4549452B2 (ja) * 1997-12-12 2010-09-22 富山化学工業株式会社 アルキルエーテル誘導体またはその塩並びにそれらを含有するカルシウム拮抗剤
JP2002532481A (ja) * 1998-12-17 2002-10-02 アメリカン・ホーム・プロダクツ・コーポレイション ５−ｈｔ１ａ受容体活性を有するピペラジンエチルアミド誘導体
KR20020067589A (ko) * 1999-12-30 2002-08-22 하. 룬트벡 아크티에 셀스카브 페닐피페라지닐 유도체
HUP0103987A3 (en) * 2001-09-28 2004-11-29 Richter Gedeon Vegyeszet Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates
JP2005538974A (ja) * 2002-07-04 2005-12-22 シュバルツ　ファルマ　アクチェンゲゼルシャフト 中枢神経系の病気を治療するドーパミン−ｄ３リガンドとして使用するためのヘテロアレーンカルボキサミド
WO2004024878A2 (en) 2002-09-14 2004-03-25 Gov't Of The U.S.A. As Represented By The Secretary Of The Department Of Health And Human Services Structurally rigid dopamine d3 receptor selective ligands and process for making them
DE10248067A1 (de) * 2002-10-07 2004-04-15 Proteosys Ag Heteroarylpropyl-Piperazine und Heteroarylpropyl-Piperidine
US20070142399A1 (en) * 2003-06-19 2007-06-21 Psychiatric Genomics, Inc. Dual function drugs and uses thereof
FR2878524B1 (fr) * 2004-12-01 2007-01-19 Bioprojet Soc Civ Ile Nouveaux derives d'arylpiperazine

Also Published As

Publication number Publication date
US20090238761A1 (en) 2009-09-24
WO2006072608A2 (en) 2006-07-13
AU2006204522A1 (en) 2006-07-13
NZ555491A (en) 2010-01-29
WO2006072608A3 (en) 2006-09-28
JP2008526715A (ja) 2008-07-24
EP1836192A2 (en) 2007-09-26

Similar Documents

Publication Publication Date Title
CA2593266A1 (en) Aryl piperazine derivatives for the treatment of neuropsychiatric disorders
US7452888B2 (en) Quinoline derivatives and their use as 5-ht6 ligands
AU679053B2 (en) Indoletetralins having dopaminergic activity
KR100359393B1 (ko) 5-ht1a 길항제로서의 피페라진유도체 및 이의 제조방법
US5532243A (en) Antipsychotic nitrogen-containing bicyclic compounds
JP6458028B2 (ja) インドール及びピロールの新規な誘導体、その製造方法及びそれを含む医薬組成物
JPH04506071A (ja) 中枢神経系活性を有する複素環系アミン
JPH06279442A (ja) ピロロ−ピリジン誘導体
KR100792186B1 (ko) 4-페닐-1-피페라지닐, -피페리디닐 및 -테트라히드로피리딜유도체
MXPA02006223A (es) Derivados de fenilpiperazina sustituida, su preparcion y uso.
US20070027139A1 (en) Piperazinyl-quinoline derivatives useful for the treatment of cns disorders
EP1660483A1 (en) 8-(1-piperazinyl)-quinoline derivatives and their use in the treatment of cns disorders
US5075303A (en) Pyridine derivatives
EP1581522B1 (en) Flavaxate derivatives as muscarinic receptor antagonists
EP0678090A1 (en) Piperazine derivatives
CA2402472A1 (en) 2,3,4,5-tetrahydro-1h-¬1,4|diazepino¬1,7a|indole compounds
WO2005037796A1 (en) Compounds and methods for treating dyslipidemia
MXPA02006498A (es) Novedosos derivados de indol.
BG108531A (bg) Нови х...'...роарилни производни, 'яхно'о пол"-аван... и използван...
CN101137645A (zh) 用于治疗神经精神病障碍的芳基哌嗪衍生物
ZA200309258B (en) 4-Piperazinylindole derivatives with 5-HT6 receptor affinity.
MX2007008044A (es) Nuevos derivados de arilpiperazina con utilidad medica
JPH09508637A (ja) ５ｈｔ２ｂレセプタ拮抗薬縮合インドール
HK1116166A (en) Aryl piperazine derivatives for the treatment of neuropsychiatric disorders
SK137597A3 (en) 1-£'omega'-(3,4-dihydro-2-naphthalenyl)alkyl| cyclic amine derivatives, process for producing the same, and medicinal composition containing the same

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20120103